Simultaneous assessment of DOACs effect on clot formation and fibrinolysis with the FibWave
Jonathan Evrard
Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium
Search for more papers by this authorVincent Maloteau
Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium
Search for more papers by this authorJean-Michel Dogné
Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium
Search for more papers by this authorCorresponding Author
Jonathan Douxfils
Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium
Qualiblood s.a., Namur, Belgium
Correspondence
Jonathan Douxfils, Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur 5000, Belgium.
Email: [email protected]
Search for more papers by this authorJonathan Evrard
Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium
Search for more papers by this authorVincent Maloteau
Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium
Search for more papers by this authorJean-Michel Dogné
Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium
Search for more papers by this authorCorresponding Author
Jonathan Douxfils
Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium
Qualiblood s.a., Namur, Belgium
Correspondence
Jonathan Douxfils, Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur 5000, Belgium.
Email: [email protected]
Search for more papers by this author
CONFLICT OF INTEREST
Among the authors, Jonathan Douxfils is CEO and founder of QUALIblood s.a. and reports personal fees from Roche, Roche Diagnostics, Stago, and Daiichi-Sankyo, outside the submitted work.
Supporting Information
| Filename | Description |
|---|---|
| ijlh13723-sup-0001-FigureS1.docxapplication/vnd.openxmlformats-officedocument.wordprocessingml.document: .docx, 571.9 KB | Figure S1 |
| ijlh13723-sup-0002-FigureS2.docxapplication/vnd.openxmlformats-officedocument.wordprocessingml.document: .docx, 122.9 KB | Figure S2 |
| ijlh13723-sup-0003-Supinfo.docxapplication/vnd.openxmlformats-officedocument.wordprocessingml.document: .docx, 114.2 KB | Supplementary Material |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Oka S, Wakui M, Fujimori Y, et al. Application of clot-fibrinolysis waveform analysis to assessment of in vitro effects of direct oral anticoagulants on fibrinolysis. Int J Lab Hematol. 2020; 42(3): 292-298. doi:10.1111/ijlh.13168
- 2Lance MD. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Thromb J. 2015; 13: 1. doi:10.1186/1477-9560-13-1
- 3Nogami K, Matsumoto T, Sasai K, Ogiwara K, Arai N, Shima M. A novel simultaneous clot-fibrinolysis waveform analysis for assessing fibrin formation and clot lysis in haemorrhagic disorders. Br J Haematol. 2019; 187(4): 518-529. doi:10.1111/bjh.16111
- 4Evrard J, Morimont L, Benyahia Z, et al. Evaluation of the analytical performances of FibWave, a new sensitive tool assessing the fibrin clot formation, to measure the effects of anticoagulants. Thromb Res. 2020; 191: 78-81. doi:10.1016/j.thromres.2020.04.029
- 5Evrard J, Morimont L, Didembourg M, et al. Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance. Int J Lab Hematol. 2021; 43: 802-812. doi: 10.1111/ijlh.13427
- 6Evrard J, Siriez R, Morimont L, et al. Optimal wavelength for the clot waveform analysis: determination of the best resolution with minimal interference of the reagents. Int J Lab Hematol. 2019; 41(3): 316-324. doi:10.1111/ijlh.12975
- 7Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost. 2001; 85(1): 5-11.
- 8Königsbrügge O, Weigel G, Quehenberger P, Pabinger I, Ay C. Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation. Clin Exp Med. 2018; 18(3): 325-336. doi:10.1007/s10238-018-0490-9
- 9Semeraro F, Incampo F, Ammollo CT, et al. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation. Thromb Res. 2016; 138: 22-29. doi:10.1016/j.thromres.2015.12.023
- 10Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost. 2010; 8(4): 790-798. doi:10.1111/j.1538-7836.2010.03739.x
- 11Wada H, Shiraki K, Matsumoto T, Ohishi K, Shimpo H, Shimaoka M. Effects of platelet and phospholipids on clot formation activated by a small amount of tissue factor. Thromb Res. 2020; 193: 146-153. doi:10.1016/j.thromres.2020.06.018
Citing Literature
